Therefore, TCZ is recommended in seriously ill patients with elevated IL-6 by the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) issued by the National Health Commission of China [7]. This evidence concerns the gene IL6 and COVID-19.